Showing results (191-200 of 228) with videos related to

Sort By:
Pageof 23
The Prostate|July 21, 2004
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOFM B Gretzer, D W Chan, C L van Rootselaar, et al.
Urology|May 1, 1994
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasesA W Partin, J D Pearson, P K Landis, et al.
Urology|October 1, 1996
Histopathologic characterization of hereditary benign prostatic hyperplasiaC B Doehring, M G Sanda, A W Partin, et al.
Urology|April 11, 2001
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendationsR Lieberman, W G Nelson, W A Sakr, et al.
The Prostate. Supplement|January 1, 1996
Clearance rate of serum-free and total PSA following radical retropubic prostatectomyA W Partin, S Piantadosi, E N Subong, et al.
The Journal of Pharmacy and Pharmacology|April 1, 1987
Particulate contaminants of intravenous medications and infusionsC M Backhouse, P R Ball, S Booth, et al.
Urology|December 1, 1996
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancerJ Pannek, E N Subong, K A Jones, et al.
The Journal of Urology|June 1, 1997
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasiaL S Marks, A W Partin, G J Gormley, et al.
Urology|May 1, 1995
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomyA W Partin, S Piantadosi, M G Sanda, et al.
Urology|December 31, 1997
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancerJ Pannek, H G Rittenhouse, C L Evans, et al.
Pageof 23